• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist.

作者信息

Hoerer Stefan, Schmid Angela, Heckel Armin, Budzinski Ralph M, Nar Herbert

机构信息

Department of Lead Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, D-88397 Biberach/Riss, Germany.

出版信息

J Mol Biol. 2003 Dec 12;334(5):853-61. doi: 10.1016/j.jmb.2003.10.033.

DOI:10.1016/j.jmb.2003.10.033
PMID:14643652
Abstract

LXRbeta belongs to the nuclear hormone receptor superfamily of ligand-activated transcription factors. Its natural ligands are supposed to be oxidised derivatives of cholesterol. Stimulation of LXRbeta by agonists activates a number of genes that are involved in the regulation of lipid metabolism and cholesterol efflux from cells. Therefore, LXRbeta may represent a novel therapeutic target for the treatment of dyslipidemia and atherosclerosis.Here, we report the X-ray crystal structure of the LXRbeta ligand-binding domain in complex with a synthetic agonist, T-0901317. This compound occupies the ligand-binding pocket of the receptor, forms numerous lipophilic contacts with the protein and one crucial hydrogen bond to His435 and stabilises the agonist conformation of the receptor ligand-binding domain. The recruitment of the AF2-region of the protein is not achieved via direct polar interactions of the ligand with protein side-chains of this helical segment, but rather via few hydrophobic contacts and probably more importantly via indirect effects involving the pre-orientation of side-chains that surround the ligand-binding pocket and form the interface to the AF2-helix. On the basis of these results we propose a binding mode and a mechanism of action for the putative natural ligands, oxidised derivatives of cholesterol.

摘要

相似文献

1
Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist.
J Mol Biol. 2003 Dec 12;334(5):853-61. doi: 10.1016/j.jmb.2003.10.033.
2
X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch.肝脏X受体β配体结合域的X射线晶体结构:由组氨酸-色氨酸开关调控
J Biol Chem. 2003 Jul 18;278(29):27138-43. doi: 10.1074/jbc.M302260200. Epub 2003 May 7.
3
The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands.肝脏X受体β的三维结构显示出一个灵活的配体结合口袋,它能够容纳根本不同的配体。
J Biol Chem. 2003 Oct 3;278(40):38821-8. doi: 10.1074/jbc.M304842200. Epub 2003 Jun 20.
4
Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist.一种植物甾醇衍生的肝脏X受体激动剂对肠道ATP结合盒转运蛋白的诱导作用。
J Biol Chem. 2003 Sep 19;278(38):36091-8. doi: 10.1074/jbc.M304153200. Epub 2003 Jul 7.
5
T0901317 is a dual LXR/FXR agonist.T0901317是一种双效肝X受体/法尼醇X受体激动剂。
Mol Genet Metab. 2004 Sep-Oct;83(1-2):184-7. doi: 10.1016/j.ymgme.2004.07.007.
6
Analysis of crystal structures of LXRbeta in relation to plasticity of the ligand-binding domain upon ligand binding.LXRβ晶体结构与配体结合后配体结合域可塑性的关系分析。
Chem Biol Drug Des. 2008 Feb;71(2):140-54. doi: 10.1111/j.1747-0285.2007.00620.x. Epub 2008 Jan 22.
7
The important role of residue F268 in ligand binding by LXRbeta.残基F268在肝脏X受体β(LXRβ)配体结合中的重要作用。
FEBS Lett. 2000 Nov 3;484(2):159-63. doi: 10.1016/s0014-5793(00)02130-x.
8
Design, structure activity relationships and X-Ray co-crystallography of non-steroidal LXR agonists.非甾体类肝X受体激动剂的设计、构效关系及X射线共结晶学
Curr Med Chem. 2008;15(2):195-209. doi: 10.2174/092986708783330584.
9
Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism.通过自调节环机制诱导人肝脏X受体α基因表达。
Mol Endocrinol. 2002 Mar;16(3):506-14. doi: 10.1210/mend.16.3.0789.
10
T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.T-0901317,一种合成的肝脏X受体配体,可抑制低密度脂蛋白受体缺陷小鼠的动脉粥样硬化发展。
FEBS Lett. 2003 Feb 11;536(1-3):6-11. doi: 10.1016/s0014-5793(02)03578-0.

引用本文的文献

1
Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma.从泽泻根茎的萜类化合物中鉴定靶向 LXRβ 的选择性激动剂。
J Mol Model. 2021 Feb 22;27(3):91. doi: 10.1007/s00894-021-04699-z.
2
Molecular characterization and homology modeling of liver X receptor in Asian seabass, Lates calcarifer: predicted functions in reproduction and lipid metabolism.尖吻鲈肝脏X受体的分子特征与同源建模:对繁殖和脂质代谢的预测功能
Fish Physiol Biochem. 2019 Apr;45(2):523-538. doi: 10.1007/s10695-019-00617-6. Epub 2019 Feb 26.
3
In silico identification of small molecules as novel LXR agonists for the treatment of cardiovascular disease and cancer.
通过计算机模拟鉴定小分子作为治疗心血管疾病和癌症的新型肝X受体激动剂。
J Mol Model. 2018 Feb 15;24(3):57. doi: 10.1007/s00894-018-3578-y.
4
Liver X receptors at the intersection of lipid metabolism and atherogenesis.肝脏X受体处于脂质代谢与动脉粥样硬化发生的交叉点。
Atherosclerosis. 2015 Sep;242(1):29-36. doi: 10.1016/j.atherosclerosis.2015.06.042. Epub 2015 Jul 2.
5
Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate.使用位点特异性抗体-药物偶联物靶向递送肝X受体激动剂。
Bioconjug Chem. 2015 Nov 18;26(11):2216-22. doi: 10.1021/acs.bioconjchem.5b00203. Epub 2015 May 20.
6
LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.LXR、前列腺癌和胆固醇:好、坏与丑。
Am J Cancer Res. 2013;3(1):58-69. Epub 2013 Jan 18.
7
Identification of novel liver X receptor activators by structure-based modeling.基于结构建模鉴定新型肝 X 受体激活剂。
J Chem Inf Model. 2012 May 25;52(5):1391-400. doi: 10.1021/ci300096c. Epub 2012 Apr 20.
8
Nuclear receptors as drug targets for metabolic disease.核受体作为代谢疾病的药物靶点。
Adv Drug Deliv Rev. 2010 Oct 30;62(13):1307-15. doi: 10.1016/j.addr.2010.07.002. Epub 2010 Jul 22.
9
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR.混杂核激素受体的进化:LXR、FXR、VDR、PXR 和 CAR。
Mol Cell Endocrinol. 2011 Mar 1;334(1-2):39-48. doi: 10.1016/j.mce.2010.06.016. Epub 2010 Jul 6.
10
Two- and three-dimensional quantitative structure-activity relationships studies on a series of liver x receptor ligands.
Open Med Chem J. 2008 Oct 7;2:87-96. doi: 10.2174/1874104500802010087.